Sanofi Files 20-F for FY 2024

Ticker: SNYNF · Form: 20-F · Filed: Feb 13, 2025 · CIK: 1121404

Sanofi 20-F Filing Summary
FieldDetail
CompanySanofi (SNYNF)
Form Type20-F
Filed DateFeb 13, 2025
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$11.85 million
Sentimentneutral

Sentiment: neutral

Topics: annual-report, foreign-issuer, pharmaceuticals

TL;DR

Sanofi's 20-F is in for 2024, check it for biz updates & financials.

AI Summary

Sanofi filed its 20-F for the fiscal year ending December 31, 2024, reporting on its operations and financial status. The filing covers its business segments, including Biopharma, and details its share structure on NASDAQ. Sanofi, formerly known as Sanofi-Aventis and Sanofi Synthelabo, is headquartered in Paris, France.

Why It Matters

This filing provides investors and analysts with a comprehensive overview of Sanofi's performance and strategic positioning for the past fiscal year, influencing investment decisions and market perception.

Risk Assessment

Risk Level: low — A 20-F filing is a routine annual report for foreign private issuers, not indicative of immediate company-specific risk.

Key Numbers

  • 2024-12-31 — Fiscal Year End (Reporting period for the 20-F)
  • 2025-02-13 — Filing Date (Date the 20-F was submitted to the SEC)

Key Players & Entities

  • Sanofi (company) — Filer of the 20-F
  • Sanofi-Aventis (company) — Former company name
  • Sanofi Synthelabo SA (company) — Former company name
  • Paris, France (location) — Company headquarters
  • NASDAQ (company) — Stock exchange where shares are listed

FAQ

What is the primary business segment highlighted in the filing?

The filing mentions the 'BiopharmaSegmentMember' for the 2023 fiscal year, indicating its significance.

What is Sanofi's former company name?

Sanofi was formerly known as Sanofi-Aventis and Sanofi Synthelabo SA.

On which stock exchange are Sanofi's shares listed?

Sanofi's Ordinary Shares and American Depository Shares are listed on the NASDAQ Global Select Market.

What is the SIC code for Sanofi?

Sanofi's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

When was the company name changed from Sanofi Synthelabo SA?

The date of the name change from Sanofi Synthelabo SA was January 4, 2001.

Filing Stats: 4,325 words · 17 min read · ~14 pages · Grade level 14.6 · Accepted 2025-02-13 13:41:37

Key Financial Figures

  • $11.85 million — Justice and agreed to pay approximately $11.85 million to resolve allegations regarding certai

Filing Documents

forward-looking statements

forward-looking statements This annual report contains certain forward-looking statements within the meaning of applicable federal securities law, including the Private Securities Litigation Reform Act of 1995, as amended. We may also make written or oral forward-looking statements in our periodic reports to the Securities and Exchange Commission on Form 6-K, in our annual report to shareholders, in our offering circulars and prospectuses, in press releases and other written materials and in oral statements made by our officers, directors or employees to third parties. Examples of such forward-looking statements include: projections of operating revenues, net income, business net income, earnings per share, business earnings per share, capital expenditures, cost savings, restructuring costs, positive or negative synergies, dividends, capital structure or other financial items or ratios; clinical studies, regulatory approvals and competition; and which we operate. Words such as "believe," "anticipate," "can," "contemplate," "could," "plan," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "objective," "target," "estimate," "project," "predict," "forecast," "ambition," "guideline," "seek," "should," "will," "goal," or the negative of these and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements involve inherent, known and unknown risks, uncertainties and assumptions associated with the

Forward-looking statements involve inherent, known and unknown risks, uncertainties and assumptions associated with the regulatory, economic, financial and competitive environment, and other factors that could cause actual future results to differ materially from those expressed or implied in the forward-looking statements. These risks, uncertainties and assumptions include risk factors, which could also affect future results and cause actual results to differ materially from those contained in any forward-looking statements, and which include those discussed under "Item 3. Key Information — D. Risk Factors." Additional risks, not currently known or that are currently considered immaterial by the Group, may have the same unfavorable effect and investors may lose all or part of their investment. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Moreover,

forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any

forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information, future developments or otherwise, except as required by law. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this annual report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In light of these risks,uncertainties and assumptions, you should not place undue reliance on any forward looking statements contained herein. You should read this annual report and the documents that we reference in this annual report and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these statements. Abbreviations Principal abbreviations used in the Annual Report on Form 20-F ADR American Depositary Receipt ADS American Depositary Share AFEP Association franaise des entreprises prives (French Association of Large Companies) AMF Autorit des marchs financiers (the French market regulator) ANDA Abbreviated New Drug Application BLA Biologic License Application BMS Bristol-Myers Squibb CEO Chief Executive Officer CER Constant exchange rates CGU Cash generating unit CHC Consumer Healthcare, Opella CHMP Committee for Medicinal Products for Human Use COVALIS Sanofi committee for internal occupational exposure limits (Comit des Valeurs Limites Internes Sanofi) CSR Corporate Social Responsibility CVR Contingent value right EFPIA European Federation of Pharmaceutical Industries and Associations

DESCRIPTION OF SECURITIES OTHER

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 177 PART II 179 Item 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 179 Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS 179 Item 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 179 Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT 180 Item 16B. CODE OF ETHICS 180 Item 16C. PRINCIPAL ACCOUNTANTS' FEES AND SERVICES 180 Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 180 Item 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 181 Item 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 181 Item 16G. CORPORATE GOVERNANCE 181 Item 16H. MINE SAFETY DISCLOSURE 183 Item 16I. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 183 Item 16J. INSIDER TRADING POLICIES 183 Item 16K. CYBERSECURITY 183 PART III 185 Item 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 185 Item 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 185 Item 19. EXHIBITS 185 SANOFI FORM 20-F 2024 1 PART I

Identity of Directors, Senior Management and Advisers

ITEM 1. Identity of Directors, Senior Management and Advisers Part I

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers N/A

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable N/A

Key Information

Item 3. Key Information A. Selected financial data N/A B. Capitalization and indebtedness N/A C. Reasons for offer and use of proceeds N/A D. Risk factors Important factors that could cause actual financial, business, research, or operating results to differ materially from expectations are disclosed in this annual report, including without limitation the following risk factors. Investors should carefully consider all the information set forth in the following risk factors and elsewhere in this document before deciding to invest in any of the Company's securities. In addition to the risks listed below, we may be subject to other material risks that as of the date of this report are not currently known to us or that we deem immaterial at this time. Risks relating to legal and regulatory matters Product liability claims could adversely affect our business, results of operations and financial condition Product liability is a significant risk for any pharmaceutical company, given that liability claims relating to our industry are unforeseeable by nature. The evolving regulatory environment worldwide (the ever-more stringent regulatory requirements applicable to the pharmaceutical industry, plus more stringent data, quality, and supply obligations) clearly impacts our potential liability, and we may incur different liability claims to what we have handled in the past, regarding their nature, scope, and level. For a detailed analysis of the regulatory environment in which we operate, refer to "Item 4. Information on the Company - B. Business Overview - B.5.3. Regulatory framework." Substantial damages have been awarded by some jurisdictions and/or settlements agreed – notably in the United States and other common law jurisdictions – against pharmaceutical companies based on claims for injuries allegedly caused using their products. Such claims can also lead to product recalls, withdrawals, or declining sales, and/or be accompanied by consumer fr

Key Information

ITEM 3. Key Information Although we continue to insure a portion of our product liability with third-party carriers, product liability coverage is increasingly difficult and costly to obtain, particularly in the United States. In the future, it is possible that self-insurance may become the sole commercially reasonable means available for managing the financial risk associated with product liability in our pharmaceuticals and vaccines businesses (see "Item 4. Information on the Company — B. Business Overview — B.8. Insurance and risk coverage"). In cases where we self-insure, the legal costs that we would bear for handling such claims, and potential damage awards to be paid to claimants, could have a negative impact on our financial condition. Due to insurance conditions, even when we have insurance coverage, recoveries from insurers may not be totally successful due to market-driven insurance limitations and exclusions. Moreover, insolvency of an insurer could affect our ability to recover claims on policies for which we have already paid a premium. Product liability claims, regardless of their merits or the ultimate success of our defense, are costly, divert management's attention, may harm our reputation, and can impact the demand for our products and generate speculative news flows and/or rumors relating to such claims. Substantial product liability claims could materially adversely affect our business, results of operations and financial condition, and/or may have an impact on market perception of our company and negatively affect our stock price. Claims and investigations relating to ethics and business integrity, competition law, marketing practices, pricing, human rights of workers and other legal matters could adversely affect our business, results of operations and financial condition Our industry is heavily regulated and legal requirements vary from country to country, and new requirements are imposed on our industry from time to time.

View Full Filing

View this 20-F filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.